Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology

Abstract

Purpose To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors. Patients and Methods The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non–small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house–developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement. Results The median duration of contracting with five sponsors was 12 months. Ten trials in 7,085 patients that covered 12 treatment regimens across 20 trial arms were collected. To date, four trials in 3,954 patients were analyzed. Source imaging data were transferred to the academic core from 97% of trial patients (n = 3,837). Tumor imaging measurements were extracted from 82% of transferred computed tomography scans (n = 3,162). Causes of extraction failure were nonmeasurable disease (n = 392), single imaging time point (n = 224), and secondary captured images (n = 59). Overall, clinically annotated imaging data were extracted in 79% of patients (n = 3,055), and the primary trial end point analysis in each trial remained representative of each original trial end point. Conclusion The sharing and analysis of source imaging data from large randomized trials is feasible and offer a rich and reusable, but largely untapped, resource for future research on novel trial-level response and progression imaging metrics.

Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway

“…The majority of newer clinical trial datasets are not yet mature or available from sponsors; nevertheless, groups are actively attempting to make these publicly available. [52] In conclusion, AI derived support tools could give clinicians an early prediction of the success of treatment with FOLFIRI plus cetuximab using conventional standard of care CT scans.…”

“…First, liver metastasis affects greater than half of CRC patients. While there was no apparent selection bias, the signature was designed for CRC patients with liver metastases with known KRAS status in a landmark trial [49][50][51][52]. The architecture of the liver parenchyma differs from other tissues such as the lung parenchyma.…”

Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging

“…First, as a proof-of-concept study, we only included patients from a single clinical trial, although the trial was multicenter and did have two distinct trial arms. In future, as the developing of the Vol-PACT project 21 , more patients from additional trials will be continuously collected to further validate the effectiveness of the DL-based criteria. For instance, recently, another two large-scale clinical trials on mCRC, the CRYSTAL 36 (NCT00154102) and the PRIME (NCT04549935) 37 , both of which contain more than one thousand patients, have already been available in the Vol-PACT.…”

Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models

“…Another approach consists in analyzing CT scans to derive serial volumetric measurements of measurable lesions instead of the simplified estimate of the longest diameters (17). Volumetric assessments are expected to outperform unidimensional measurements from RECIST as they are more sensitive to changes in dynamics.…”

“…The use and benefit of more precise assessment of tumor burden through volumetric assessments are also being actively investigated (17). It is expected that a more precise and sensitive assessment of tumor burden will improve the predictivity of the models, particularly when small cohorts are considered.…”